Between the Biotech Waves
Between the Biotech Waves—discussing recent developments and market dynamics impacting the biotech sector.
Between the Biotech Waves
Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics
•
Nessan Bermingham PhD
•
Season 1
•
Episode 30
Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research and Manufacturers of America.
